



Medicines & Healthcare products
Regulatory Agency

MHRA Central Freedom of
Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

[MHRA Website](#)

Our Ref: **FOI2026/00254**

27 March 2026

Dear 

Thank you for your Freedom of Information (Foi) request received on 5 March. You wrote:

I am emailing for an updated FOI request for all the information in the below report (FOI 22/480) ran from its run date of 09/03/2022 to present day.

All UK spontaneous suspected adverse drug reaction reports received between 09/03/2022 and March 2026 for the Human Papilloma virus vaccine

[https://assets.publishing.service.gov.uk/media/62975e978fa8f503921c1535/FOI_22_480-1.pdf#:~:text=FOI%2022/480%20-%20HPV%20vaccine:%20All%20UK,received%20between%2018/02/2007%20and%2018/02/2022%20for%20the.>](https://assets.publishing.service.gov.uk/media/62975e978fa8f503921c1535/FOI_22_480-1.pdf#:~:text=FOI%2022/480%20%2D%20HPV%20vaccine:%20All%20UK,received%20between%2018/02/2007%20and%2018/02/2022%20for%20the.<https://assets.publishing.service.gov.uk/media/62975e978fa8f503921c1535/FOI_22_480-1.pdf#:~:text=FOI%2022/480%20-%20HPV%20vaccine:%20All%20UK,received%20between%2018/02/2007%20and%2018/02/2022%20for%20the.>)

MHRA Response

We confirm that we hold the information you have requested.

It may be helpful to firstly provide some background information to allow interpretation of this data. The Yellow Card scheme is the UK system for collecting and monitoring information on suspected adverse drug reactions (ADRs). The scheme is run by the MHRA and currently relies on voluntary reporting of suspected ADRs by health professionals and patients. There is also a legal obligation for pharmaceutical companies to report serious ADR reports for their drugs. All reports, including from patients, are reviewed through signal detection processes to identify previously unrecognised concerns about medicines and to consider if further action is necessary.

Further to your request, I can confirm the Yellow Card scheme has received a total of 714 UK spontaneous suspected ADR reports associated with Human Papilloma Virus (HPV) vaccine between 1st January 2022 and 23rd March 2026.

Please find the attached Vaccine Analysis Print (VAP) for HPV vaccine. This VAP contains complete data for all UK spontaneous suspected adverse reactions, or side effects reported between 1st January 2022 and 23rd March 2026. Please refer to the attached information sheet for guidelines on how to interpret this VAP.

If you plan to use this information for media publication purposes, you should contact our news centre who can provide any additional context or comment. You can contact them on 020 3080 7651 or by email at newscentre@mhra.gov.uk.

When considering the spontaneous ADR data detailed above, it is important to be aware of the following points:

- A reported reaction does not necessarily mean it has been caused by the medicine or medicinal product, only that the reporter had a suspicion it may have. The fact that symptoms or events occur after use of a product, and are reported via the Yellow Card scheme, does not in itself mean that they are proven to have been caused by the product. Underlying or concurrent illnesses may be responsible and such events can also be coincidental.
- It is also important to note that Yellow Card data cannot be used to determine the incidence of a reaction or to compare the side effect profiles of different medicines or vaccines. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, the extent of use of a particular drug or vaccine and may be stimulated by promotion and publicity about a drug. Reporting tends to be highest for newly introduced medicines or vaccines during the first one to two years on the market and then falls over time.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

Re-use of our information

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>